Related content

Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy

By Kinoshita Manabu   Hashimoto Naoya   Izumoto Shuichi   Okita Yoshiko   Kagawa Naoki   Maruno Motohiko   Ohnishi Takanori   Arita Norio   Yoshimine Toshiki  

Journal of Neuro-Oncology, Vol. 99, Iss. 1, 2010-08 ,pp. : 95-101

Springer Publishing Company

Access to resources Recommend Favorite

Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience

By Silvani A.   Salmaggi A.   Eoli M.   Lamperti E.   Broggi G.   Marras C.   Fariselli L.   Milanesi I.   Fiumani A.   Gaviani P.   Erbetta A.   Giovagnoli A.   Pollo B.   Botturi A.   Boiardi A.  

Journal of Neuro-Oncology, Vol. 82, Iss. 3, 2007-05 ,pp. : 273-279

Springer Publishing Company

Access to resources Recommend Favorite

Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma

By Gerber David   Grossman Stuart   Batchelor Tracy   Ye Xiaobu  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 817-823

Springer Publishing Company

Access to resources Recommend Favorite

Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases

By                    

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 949-953

Science Publishers

Access to resources Recommend Favorite

Primary central nervous system lymphoma mimicking recurrent depressive disorder: A case report

By            

Oncology Letters, Vol. 9, Iss. 4, 2015-01 ,pp. : 1819-1821

Spandidos Publications

Access to resources Recommend Favorite